IPP Bureau
Abbott’s Volt PFA System gets FDA nod
By IPP Bureau - December 24, 2025
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Enveda launches Phase 1 trial for first-in-class Oral IBD therapy
By IPP Bureau - December 24, 2025
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Asahi Kasei Pharma to move R&D hub to Shonan iPark in 2027
By IPP Bureau - December 24, 2025
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
Neurocrine’s Valbenazine fails to show benefit in largest dyskinetic cerebral palsy trial
By IPP Bureau - December 24, 2025
Adverse events were consistent with valbenazine’s established safety profile
Novo Nordisk’s Wegovy pill approved in US as first oral GLP-1 for weight management
By IPP Bureau - December 23, 2025
Wegovy pill showed a mean weight loss of 16.6% in the OASIS 4 trial
Bayer wins Japan nod for finerenone in broad heart failure population
By IPP Bureau - December 23, 2025
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
China approves first-in-class TGCT drug, marking global first for pimicotinib
By IPP Bureau - December 23, 2025
FDA grants breakthrough therapy designation to Enhertu for high-risk early breast cancer
By IPP Bureau - December 23, 2025
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
SRM Global Hospitals performs Tamil Nadu’s first TactiFlex radiofrequency ablation to save 80-yr-old patient
By IPP Bureau - December 23, 2025
TactiFlex, the world’s first catheter with a flexible tip and contact?force sensing, allows doctors to deliver energy precisely and safely.
LATIFY Phase III trial of Ceralasertib fails to improve survival in advanced lung cancer
By IPP Bureau - December 23, 2025
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
FDA go-ahead to Roche’s one-minute follicular lymphoma therapy
By IPP Bureau - December 23, 2025
Full approval will depend on verification of clinical benefit in a confirmatory trial
Zambon Biotech launches European Phase 3b trial for innovative Parkinson’s drug
By IPP Bureau - December 23, 2025
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
By IPP Bureau - December 23, 2025
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
Glenmark Pharmaceuticals USA launches Epinephrine Injection USP, multiple-dose vial
By IPP Bureau - December 23, 2025
According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market2 achieved annual sales of approximately $67.6 million
Biocon Biologics expands FKB deal to secure global rights for Adalimumab biosimilar
By IPP Bureau - December 23, 2025
Production at Biocon Biologics’ own facilities is scheduled to begin once technology transfers and regulatory approvals are finalized
